Clinical Trial Update: SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating SPI-62 for hypercortisolism due to autonomous cortisol secretion from a benign adrenal tumor has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autonomous Cortisol Secretion
• Cushing Syndrome Acth-independent

Drugs mentioned

• SPI-62

Snippet

Sponsor: Sparrow Pharmaceuticals | Conditions: Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome | Phase 2 | Status: COMPLETED